Terms: = Lung cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Clinical Outcome
19 results:
1. C-myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
2. Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma.
Zeng L; Liang L; Fang X; Xiang S; Dai C; Zheng T; Li T; Feng Z
Funct Integr Genomics; 2023 Jul; 23(3):221. PubMed ID: 37400733
[TBL] [Abstract] [Full Text] [Related]
3. Evaluate the Prognosis of
Cao J; J Gu J; Liang Y; Wang B
Technol Cancer Res Treat; 2022; 21():15330338221138213. PubMed ID: 36524293
[No Abstract] [Full Text] [Related]
4. mycN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F
Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422
[TBL] [Abstract] [Full Text] [Related]
5. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
6. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma.
Bao X; Shi R; Zhao T; Wang Y
Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651
[TBL] [Abstract] [Full Text] [Related]
7. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses.
Owonikoko TK; Niu H; Nackaerts K; Csoszi T; Ostoros G; Mark Z; Baik C; Joy AA; Chouaid C; Jaime JC; Kolek V; Majem M; Roubec J; Santos ES; Chiang AC; Speranza G; Belani CP; Chiappori A; Patel MR; Czebe K; Byers L; Bahamon B; Li C; Sheldon-Waniga E; Kong EF; Williams M; Badola S; Shin H; Bedford L; Ecsedy JA; Bryant M; Jones S; Simmons J; Leonard EJ; Ullmann CD; Spigel DR;
J Thorac Oncol; 2020 Feb; 15(2):274-287. PubMed ID: 31655296
[TBL] [Abstract] [Full Text] [Related]
8. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P; Del Re M; Minari R; Rofi E; Buti S; Restante G; Squadrilli A; Crucitta S; Casartelli C; Gnetti L; Azzoni C; Bottarelli L; Petrini I; Cosenza A; Ferri L; Rapacchi E; Danesi R; Tiseo M
Lung Cancer; 2019 May; 131():78-85. PubMed ID: 31027702
[TBL] [Abstract] [Full Text] [Related]
9. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/myc pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract] [Full Text] [Related]
10. Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival.
Qian Z; Zhou T; Gurguis CI; Xu X; Wen Q; Lv J; Fang F; Hecker L; Cress AE; Natarajan V; Jacobson JR; Zhang DD; Garcia JG; Wang T
Sci Rep; 2015 Nov; 5():16889. PubMed ID: 26596768
[TBL] [Abstract] [Full Text] [Related]
11. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL; Wu JY; Wu ZY; Shen JH; Xu XE; Chen B; Wang SH; Li EM; Xu LY
Int J Cancer; 2015 Mar; 136(6):E569-77. PubMed ID: 25220908
[TBL] [Abstract] [Full Text] [Related]
12. CITED2 functions as a molecular switch of cytokine-induced proliferation and quiescence.
Chou YT; Hsieh CH; Chiou SH; Hsu CF; Kao YR; Lee CC; Chung CH; Wang YH; Hsu HS; Pang ST; Shieh YS; Wu CW
Cell Death Differ; 2012 Dec; 19(12):2015-28. PubMed ID: 22814619
[TBL] [Abstract] [Full Text] [Related]
13. Progressive lung cancer determined by expression profiling and transcriptional regulation.
Han N; Dol Z; Vasieva O; Hyde R; Liloglou T; Raji O; Brambilla E; Brambilla C; Martinet Y; Sozzi G; Risch A; Montuenga LM; ; Brass A; Field JK
Int J Oncol; 2012 Jul; 41(1):242-52. PubMed ID: 22469662
[TBL] [Abstract] [Full Text] [Related]
14. Oligopeptides impairing the myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract] [Full Text] [Related]
15. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer.
Toledo G; Sola JJ; Lozano MD; Soria E; Pardo J
Mod Pathol; 2004 Apr; 17(4):440-8. PubMed ID: 14976524
[TBL] [Abstract] [Full Text] [Related]
16. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
Kubokura H; Tenjin T; Akiyama H; Koizumi K; Nishimura H; Yamamoto M; Tanaka S
Ann Thorac Cardiovasc Surg; 2001 Aug; 7(4):197-203. PubMed ID: 11578259
[TBL] [Abstract] [Full Text] [Related]
17. High level amplification of 1p32-33 and 2p22-24 in small cell lung carcinomas.
Lui WO; Tanenbaum DM; Larsson C
Int J Oncol; 2001 Sep; 19(3):451-7. PubMed ID: 11494021
[TBL] [Abstract] [Full Text] [Related]
18. L-myc allelotype in renal cell carcinoma.
Presti JC; Hinckley J; Reuter VE
Cancer Genet Cytogenet; 1996 May; 88(1):66-8. PubMed ID: 8630982
[TBL] [Abstract] [Full Text] [Related]
19. N-myc protein expression in human breast carcinoma: prognostic implications.
Mizukami Y; Nonomura A; Takizawa T; Noguchi M; Michigishi T; Nakamura S; Ishizaki T
Anticancer Res; 1995; 15(6B):2899-905. PubMed ID: 8669886
[TBL] [Abstract] [Full Text] [Related]
